APA (7th ed.) Citation

Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., . . . Cassaniti, I. (2022). Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: An update after 6 months of follow-up. ESMO open, 7(1), 100359. https://doi.org/10.1016/j.esmoop.2021.100359

Chicago Style (17th ed.) Citation

Lasagna, A., et al. "Analysis of the Humoral and Cellular Immune Response After a Full Course of BNT162b2 Anti-SARS-CoV-2 Vaccine in Cancer Patients Treated with PD-1/PD-L1 Inhibitors with or Without Chemotherapy: An Update After 6 Months of Follow-up." ESMO Open 7, no. 1 (2022): 100359. https://doi.org/10.1016/j.esmoop.2021.100359.

MLA (9th ed.) Citation

Lasagna, A., et al. "Analysis of the Humoral and Cellular Immune Response After a Full Course of BNT162b2 Anti-SARS-CoV-2 Vaccine in Cancer Patients Treated with PD-1/PD-L1 Inhibitors with or Without Chemotherapy: An Update After 6 Months of Follow-up." ESMO Open, vol. 7, no. 1, 2022, p. 100359, https://doi.org/10.1016/j.esmoop.2021.100359.